We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00138866
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : October 13, 2010
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to find out if risedronate works for the treatment of osteoporosis for people with spinal cord injury.

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: Risedronate Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury
Study Start Date : November 2004
Primary Completion Date : January 2009
Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Change in bone mineral density of the distal femur between baseline and 18-months [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. Change in bone mineral density of the hips and proximal tibia between baseline and 18-months [ Time Frame: 18 months ]
  2. The change in biochemical bone markers of bone turnover between baseline and 18-months [ Time Frame: 18 months ]
  3. The frequency and severity of adverse events [ Time Frame: 18 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Traumatic spinal cord injury of greater than 18 months
  • Osteopenia or osteoporosis of the hip
  • Must be able to swallow tablets and sit upright

Exclusion Criteria:

  • Bilateral heterotopic ossification
  • Bilateral lower extremity metal implants
  • Pregnant or lactating females
  • Paget's disease
  • Osteomalacia
  • Steroid induced bone loss
  • Untreated parathyroid or thyroid disease
  • Symptomatic hypocalcemia or hypophosphatemia
  • Treatment in the last year with calcitonin, fluoride or anabolic steroids
  • Current treatment with prednisone
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00138866

Canada, Ontario
Toronto Rehab, Lyndhurst Centre
Toronto, Ontario, Canada, M4G 3V9
Sponsors and Collaborators
Toronto Rehabilitation Institute
The Physicians' Services Incorporated Foundation
St. Joseph's Health Care London
Principal Investigator: B. Cathy Craven, MD, FRCPC Toronto Rehabilitation Institute
More Information

Responsible Party: Dr. BC Craven, Toronto Rehab Institute
ClinicalTrials.gov Identifier: NCT00138866     History of Changes
Other Study ID Numbers: TRI REB #04-016
PSI #03-52
First Posted: August 30, 2005    Key Record Dates
Last Update Posted: October 13, 2010
Last Verified: July 2008

Keywords provided by Toronto Rehabilitation Institute:
Spinal cord injury

Additional relevant MeSH terms:
Spinal Cord Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs